Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CETP | P11597 | 3/20 | 0.48 |
| ▸ | CNR2 | P34972 | 1/20 | 0.44 |
| ▸ | CTRC | Q99895 | 1/20 | 0.43 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2679107 | 1.00 | CETP (0.48) | CETPCNR2CTRCCSNK1EMEN1 | |
| SCHEMBL1359364 | 0.89 | MMP2 (0.50) | CETPCNR2 | |
| SCHEMBL1358863 | 0.89 | MMP2 (0.50) | CETPCNR2 | |
| SCHEMBL4969361 | 0.89 | MMP2 (0.50) | CETPCNR2 | |
| SCHEMBL1358859 | 0.89 | MMP2 (0.50) | CETPCNR2 | |
| SCHEMBL29893945 | 0.89 | MMP2 (0.50) | CETPCNR2 | |
| SCHEMBL1359365 | 0.89 | MMP2 (0.50) | CETPCNR2 | |
| SCHEMBL1358862 | 0.89 | MMP2 (0.50) | CETPCNR2 | |
| SCHEMBL1358861 | 0.89 | MMP2 (0.50) | CETPCNR2 | |
| SCHEMBL24437020 | 0.88 | CETP (0.49) | CETPCNR2CTRCCSNK1EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105131051-B | Synthetic glucopyranosyl lipid adjuvants | 传染性疾病研究院 | 2020-07-10 | — | — | CN | disclosed |
| US-10632191-B2 | Synthetic glucopyranosyl lipid adjuvants | INFECTIOUS DISEASE RESEARCH INSTITUTE (US) | 2020-04-28 | — | — | US | disclosed |
| EP-3124491-B1 | SYNTHETIC GLUCOPYRANOSYL LIPID ADJUVANTS AND VACCINE COMPOSITIONS AS WELL AS PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | INFECTIOUS DISEASE RES INST (US) | 2019-10-30 | — | — | EP | disclosed |
| US-20180028649-A1 | SYNTHETIC GLUCOPYRANOSYL LIPID ADJUVANTS | INFECTIOUS DISEASE RESEARCH INSTITUTE (US) | 2018-02-01 | — | — | US | disclosed |
| US-9814772-B2 | Synthetic glucopyranosyl lipid adjuvants | INFECTIOUS DISEASE RESEARCH INSTITUTE (US) | 2017-11-14 | — | — | US | disclosed |
| US-20170182155-A1 | SYNTHETIC GLUCOPYRANOSYL LIPID ADJUVANTS | INFECTIOUS DISEASE RES INST (US) | 2017-06-29 | — | — | US | disclosed |
| EP-3124491-A1 | SYNTHETIC GLUCOPYRANOSYL LIPID ADJUVANTS AND VACCINE COMPOSITIONS CONTAINING THEM | Infectious Disease Research Institute (US) | 2017-02-01 | — | — | EP | disclosed |
| US-9480740-B2 | Synthetic glucopyranosyl lipid adjuvants | INFECTIOUS DISEASE RESEARCH INSTITUTE (US) | 2016-11-01 | — | — | US | disclosed |
| EP-2437753-B1 | SYNTHETIC GLUCOPYRANOSYL LIPID ADJUVANTS AND VACCINE COMPOSITIONS CONTAINING THEM | INFECTIOUS DISEASE RES INST (US) | 2016-08-31 | — | — | EP | disclosed |
| CN-102481312-B | Synthetic Glucopyranosyl Lipid Adjuvants | INFECTIOUS DISEASE RES INST | 2015-07-15 | — | — | CN | disclosed |
| US-20140322268-A1 | SYNTHETIC GLUCOPYRANOSYL LIPID ADJUVANTS | INFECTIOUS DISEASE RESEARCH INSTITUTE (US) | 2014-10-30 | — | — | US | disclosed |
| US-8722064-B2 | Synthetic glucopyranosyl lipid adjuvants | INFECTIOUS DISEASE RESEARCH INSTITUTE (US) | 2014-05-13 | — | — | US | disclosed |
| CN-102481312-A | Synthetic Glucopyranosyl Lipid Adjuvants | INFECTIOUS DISEASE RES INST | 2012-05-30 | — | — | CN | disclosed |
| US-20100310602-A1 | SYNTHETIC GLUCOPYRANOSYL LIPID ADJUVANTS | INFECTIOUS DISEASE RESEARCH INSTITUTE (US) | 2010-12-09 | — | — | US | disclosed |
| CN-1434795-A | Acylated Pseudodipeptides with Functionalized Auxiliary Branches | OM PHARMA (CH) | 2003-08-06 | — | — | CN | disclosed |
| US-5792840-A | SUBSTITUTED GLUCOPYRANOSYL PHOSPHATES | SANKYO COMPANY, LIMITED (JP) | 1998-08-11 | — | — | US | disclosed |
| EP-0437016-B1 | Lipid A analogues having immunoactivating and anti-tumour activity | SANKYO CO (JP) | 1996-05-01 | — | — | EP | disclosed |
| US-5399720-A | Production of oxetanones | HOFFMANN-LA ROCHE INC. (US) | 1995-03-21 | — | — | US | disclosed |
| US-5245056-A | PRODUCTION OF OXETANONES | HOFFMANN-LA ROCHE INC. (US) | 1993-09-14 | — | — | US | disclosed |
| EP-0437016-A2 | Lipid A analogues having immunoactivating and anti-tumour activity | Sankyo Company Limited (JP) | 1991-07-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140322268-A1 | SYNTHETIC GLUCOPYRANOSYL LIPID ADJUVANTS | B3GAT3, GLA, LGALS8 | CETP 2252/4885CNR2 3295/4885CTRC 4137/4885 |
| US-10632191-B2 | Synthetic glucopyranosyl lipid adjuvants | B3GAT3, GLA, LGALS8 | CETP 2329/4885CNR2 3279/4885CTRC 4162/4885 |
| US-20100310602-A1 | SYNTHETIC GLUCOPYRANOSYL LIPID ADJUVANTS | B3GAT3, GLA, LGALS8 | CETP 2252/4885CNR2 3295/4885CTRC 4137/4885 |
| US-20180028649-A1 | SYNTHETIC GLUCOPYRANOSYL LIPID ADJUVANTS | B3GAT3, GLA, LGALS8 | CETP 2329/4885CNR2 3279/4885CTRC 4162/4885 |
| US-20170182155-A1 | SYNTHETIC GLUCOPYRANOSYL LIPID ADJUVANTS | B3GAT3, GLA, LGALS8 | CETP 2252/4885CNR2 3295/4885CTRC 4137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.